Market Price

1.56 

0.18 13.0%

as of May 19 '22

52 Week Range:

1.25 5.85


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Jun '13 Jun '14 Jun '15 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 2.41
2.05
2.31
1.26
1.98
1.36
growth rate -14.9% 12.7% -45.5% 57.1% -31.3%
Earnings BIT -11.52
-24.64
-43.12
-72.80
-80.66
-82.37
-139.77
-133.41
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -4.35
-6.36
-6.36
-6.36
-6.36
-6.36
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -293.14
-44.31
-12.12
-27.20
-27.20
-34.24
-59.86
-41.12
-34.34
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -16.48
-35.48
-38.00
-42.46
-74.04
-55.97
-57.78
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -16.83
-35.93
-38.98
-43.49
-66.41
-51.52
-53.32
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 0.40
1.02
11.03
4.94
3.10
9.46
3.51
10.19
6.64
growth rate 155.0% 981.4% -33.1% -37.3% 205.2% -62.9% 190.3% -34.8%
Quick Ratio 0.29
1.00
10.83
4.54
2.96
9.14
3.21
9.95
6.45
growth rate 244.8% 983.0% -35.3% -34.8% 208.8% -64.9% 210.0% -35.2%
Leverage 23.04
1.16
1.41
1.39
1.12
1.47
1.32
2.28
growth rate -95.0% 10.3% -1.4% -19.4% 31.3% -10.2% 72.7%
Balance Sheet Jun '13 Jun '14 Jun '15 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 1.90
0.00
0.74
7.73
11.66
18.16
19.28
20.72
growth rate -99.8% 18,500.0% 938.6% 50.9% 55.7% 6.2% 7.5%
Acct.Payable 1.02
1.98
7.88
11.35
8.38
4.08
6.36
6.39
growth rate 95.1% 297.8% 44.0% -26.2% -51.3% 55.7% 0.5%
Cur.Assets 54.32
295.08
263.05
198.75
230.18
231.10
120.49
398.15
growth rate 443.3% -10.9% -24.4% 15.8% 0.4% -47.9% 230.5%
Total Assets 55.75
300.65
285.82
234.52
281.15
276.74
181.54
451.14
growth rate 439.2% -4.9% -18.0% 19.9% -1.6% -34.4% 148.5%
Cash 51.49
229.05
194.26
158.78
84.04
68.38
50.41
56.88
growth rate 344.8% -15.2% -18.3% -47.1% -18.6% -26.3% 12.8%
Inventory 1.19
3.76
1.09
1.46
2.09
growth rate 215.4% -71.1% 34.2% 43.0%
Cur.Liabilities 53.33
26.77
27.89
40.27
74.31
24.44
34.34
39.07
growth rate -49.8% 4.2% 44.4% 84.5% -67.1% 40.5% 13.8%
Liabilities 53.33
41.65
50.83
68.37
78.16
29.85
57.91
109.92
growth rate -21.9% 22.0% 34.5% 14.3% -61.8% 94.0% 89.8%
LT Debt 26.49
growth rate
Equity 2.42
259.00
234.99
166.14
202.98
246.89
123.64
341.23
growth rate 10,601.3% -9.3% -29.3% 22.2% 21.6% -49.9% 176.0%
Common Shares 71.00
71.00
36.00
0.68
71.00
88.00
97.00
105.00
142.00
156.00
growth rate 0.0% -49.3% -98.1% 10,310.6% 23.9% 10.2% 8.3% 35.2% 9.9%
Cash Flow Statement Jun '13 Jun '14 Jun '15 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 1.37
5.08
12.75
11.51
24.64
3.91
1.59
2.34
growth rate 271.9% 150.9% -9.7% 114.2% -84.1% -59.3% 47.1%
Cash From OA 36.84
-29.67
-31.61
-48.17
-54.32
-104.39
-112.51
-53.59
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -0.42
-0.62
-0.92
-1.15
-0.25
-0.90
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 16.00
189.38
189.38
0.02
108.34
growth rate 1,083.3% 0.0% -100.0% 637,205.9%
FCF -8.00
36.00
-38.00
-44.35
-61.00
-79.00
-109.00
-116.00
-56.00
2.00
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Income Statement Jun '13 Jun '14 Jun '15 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 0.83
9.87
14.49
14.20
37.83
59.51
1.12
3.96
growth rate 1,096.5% 46.8% -2.0% 166.5% 57.3% -98.1% 252.8%
Op.Income -11.52
-24.64
-43.12
-72.80
-80.66
-82.37
-139.77
-133.41
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -11.53
-21.81
-39.37
-70.69
-69.69
-95.02
-136.92
-129.93
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -11.60
-22.06
-39.51
-71.58
-70.14
-95.51
-137.17
-130.09
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -0.12
-0.16
-1.02
-1.02
-0.78
-0.96
-1.32
-0.90
-1.02
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 0.83
9.87
14.49
-49.59
-49.56
-38.76
-96.38
-87.61
growth rate 1,096.5% 46.8% -100.0% 0.0% 0.0% 0.0% 0.0%
R&D 9.58
24.14
39.85
63.79
87.39
97.50
97.50
91.57
growth rate 152.1% 65.1% 60.1% 37.0% 11.6% 0.0% -6.1%

Quarterly Statements

Item Name Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Earnings BIT -35.88
-37.51
-37.89
-39.31
-42.18
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Acct.Receivable 13.92
20.72
31.14
39.91
45.09
growth rate 48.9% 50.3% 28.2% 13.0%
Acct.Payable 4.03
6.39
4.12
6.98
4.78
growth rate 58.5% -35.6% 69.5% -31.4%
Cur.Assets 426.73
398.15
359.29
337.34
300.45
growth rate -6.7% -9.8% -6.1% -10.9%
Total Assets 479.02
451.14
411.58
389.79
353.53
growth rate -5.8% -8.8% -5.3% -9.3%
Cash 78.47
56.88
32.43
50.45
42.92
growth rate -27.5% -43.0% 55.6% -14.9%
Inventory 2.49
2.09
1.58
1.59
1.29
growth rate -16.2% -24.5% 1.0% -19.2%
Cur.Liabilities 34.90
39.07
31.31
41.42
41.14
growth rate 12.0% -19.9% 32.3% -0.7%
Liabilities 102.82
109.92
102.42
111.85
112.55
growth rate 6.9% -6.8% 9.2% 0.6%
LT Debt
growth rate
Equity 376.21
341.23
309.16
277.94
240.98
growth rate -9.3% -9.4% -10.1% -13.3%
Common Shares 1.33
1.33
1.33
1.34
1.34
growth rate 0.0% 0.5% 0.4% 0.1%
Cash Flow Statement Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Capital Expenditures 0.71
1.17
1.15
1.77
1.63
growth rate 63.5% -1.3% 53.8% -7.8%
Cash From OA -16.32
-29.22
-46.54
-31.46
-45.20
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -17.03
-30.38
-47.69
-33.23
-46.83
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Sales 1.19
1.50
0.43
3.10
1.20
growth rate 25.9% -71.1% 613.1% -61.1%
Op.Income -35.88
-37.51
-37.89
-39.31
-42.18
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -35.42
-36.56
-37.47
-38.99
-42.19
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -35.43
-36.61
-37.76
-39.07
-42.40
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit -22.87
-24.28
-24.07
-25.77
-27.01
growth rate 0.0% 0.0% 0.0% 0.0%
R&D 25.78
25.78
growth rate 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -6.36 -1.58
EPS / Growth -0.99

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 49.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 40.0% 49.6% 49.6%
Future PE 0.01 0.01 33.09
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.